This is the authors' abstract. We don't add key points for this paper.
We report the case of a 39-year-old woman who presented with generalized malaise; lymphadenopathy; arthritis; dactylitis; ecchymosis; acute onycholysis; and a red, nonpruritic, nonscaly, mottled rash on the right breast 24 hours after the first injections of ixekizumab for psoriasis and psoriatic arthritis.Ixekizumab is a humanized IgG4 monoclonal antibody that binds to IL-17A.Adverse events of ixekizumab include infection, inflammatory bowel disease, candidiasis and tinea infections, severe injection-site reactions, arthralgia, headache, infections, neutropenia, and thrombocytopenia.Other biologics, specifically tumor necrosis factor (TNF) inhibitors, have been reported to cause onycholysis attributed to immune dysregulation.We propose that ixekizumab alters the inflammatory cascade that underlies the induction of acute onycholysis and arthritis.Cutis.2022;109:E33-E35. Case ReportA 39-year-old woman who was otherwise healthy presented with fatigue, malaise, a resolving rash, focal lymphadenopathy, increasing distal arthritis, dactylitis, resolving ecchymoses, and acute onycholysis of 1 week's duration that developed 13 days after initiating ixekizumab.The patient had a history of psoriasis and psoriatic arthritis for more than 10 years.She had been successfully treated in the past for psoriasis with adalimumab for several years; however, adalimumab was discontinued after an episode of Clostridium difficile colitis.The patient had a negative purified protein derivative (tuberculin) test prior to starting biologics as she works in the health care field.Routine follow-up purified protein derivative (tuberculin) test was positive.She discontinued all therapy for psoriasis and psoriatic arthritis prior to being appropriately treated for 6 months under the care of infectious disease physicians.She then had several pregnancies and chose to restart biologic treatment after weaning her third child from breastfeeding, as her skin and joint disease were notably flaring.Ustekinumab was chosen to shift treatment away from tumor necrosis factor (TNF) α inhibitors.The patient's condition was under relatively good control for 1 year; however, she experienced notable gastrointestinal tract upset (ie, intermittent diarrhea and constipation), despite multiple negative tests for C difficile.The patient was referred to see a gastroenterologist but never followed up.Due to long-term low-grade gastrointestinal problems, ustekinumab was discontinued, and the gastrointestinal symptoms resolved without treatment.Given the side effects noted with TNF-α and IL-12/23 inhibitors and the fact that the patient's cutaneous and joint disease were notable, the decision was made to start Severe Acute Systemic Reaction After the First Injections of Ixekizumab
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
John Pappas (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: